echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > After PROTAC: Looking forward to a breakthrough in lysosomal degradation technology

    After PROTAC: Looking forward to a breakthrough in lysosomal degradation technology

    • Last Update: 2021-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Targeted protein degradation (TPD) technology uses two naturally occurring protein degradation systems in cells, namely Ubiquitin-proteasome system (UPS) and lysosomal degradation pathways to achieve disease-related The specific and efficient degradation of protein can achieve the effect of disease treatment.


    The difference between ubiquitination-proteasome system (UPS) and lysosomal degradation pathway

    Source: Kailaiying, Biological Jingwei, Yingdi Capital

    Source: Kailaiying, Biological Jingwei, Yingdi Capital

    The lysosomal degradation pathway is mainly based on two pathways: endocytic vesicles and autophagy: based on endocytic vesicles, a targeted chimera system (Lysosome targeting chimaeras, LYTACs) is established; based on autophagy, including autophagy mediated by chaperone (Chaperone-mediated autophagy, CMA), Autophagy-Targeting Chimera (Autophagy-Targeting Chimera, AUTAC), and Autophagosome-tethering compound (ATTEC).


    Schematic diagram of the mechanism of action of the lysosomal degradation pathway

    Source: Literature [5]

    Source: Literature [5]

    The technical differences between them (LYTAC, CMA, AUTAC, ATTEC, etc.


    Source: Kailaiying, Biological Jingwei, Yingdi Capital

    Source: Kailaiying, Biological Jingwei, Yingdi Capital

    Research situation

    1.


    1.


    Picture source: Literature [1]

    Picture source: Literature [1]

    In their research, oligomannose-6-phosphate (M6Pn) was covalently cross-linked to the specific antibody of the target protein.


    2.


    2.


    Image source: I love biochemical public account

    Image source: I love biochemical public account

    Fan et al.


    3.


    3.


    Picture source: Literature [3]

    Picture source: Literature [3]

    However, the autophagy process has many steps and is extremely complicated, and there will be many influencing factors, so the stability is poor.


    4.


    4.


    Picture source: Literature [4]

    Picture source: Literature [4]

    Outlook

    Outlook

    In recent years, CMA, LYTAC, ATTEC, and AUTAC degradation methods based on lysosomal degradation pathways that have emerged in recent years have provided us with new ideas in the degradation of target proteins, and further expanded the range of target proteins of TPD drugs.


    references

    references

    [1] Banik SM, Pedram K, Wisnovsky S, etal.


    [1] Banik SM, Pedram K, Wisnovsky S, etal.
    Lysosome-targeting chimaeras for degradation of extracellular proteins.
    Nature, 2020, 584(7820):291-297.

    [2] Fan XL, Jin WY, Lu J, et al.
    Rapid andreversible knockdown of endogenous proteins by peptidedirected lysosomaldegradation.
    Nat Neurosci, 2014,17(3): 471-480.

    [2] Fan XL, Jin WY, Lu J, et al.
    Rapid andreversible knockdown of endogenous proteins by peptidedirected lysosomaldegradation.
    Nat Neurosci, 2014,17(3): 471-480.

    [3] Takahashi D, Moriyama J, Nakamura T, etal.
    AUTACs: cargo-specific degraders using selective autophagy.
    Mol Cell, 2019,76(5): 797-810.
    e10.

    [3] Takahashi D, Moriyama J, Nakamura T, etal.
    AUTACs: cargo-specific degraders using selective autophagy.
    Mol Cell, 2019,76(5): 797-810.
    e10.

    [4] Li ZY, Wang C, Wang ZY, et al.
    Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds.
    Nature, 2019, 575(7781): 203-209.

    [4] Li ZY, Wang C, Wang ZY, et al.
    Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds.
    Nature, 2019, 575(7781): 203-209.

    [5]Chen SP, Yang H, Jiang JL, et al.
    Researchprogress on targeted protein degradation technology and its applications indiseases therapy.
    Chin J Biotech, 2021, 37(12): 1-18.

    [5]Chen SP, Yang H, Jiang JL, et al.
    Researchprogress on targeted protein degradation technology and its applications indiseases therapy.
    Chin J Biotech, 2021, 37(12): 1-18.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.